Advances in Biomarkers for Neurodegenerative Diseases: From Molecular Discovery to Early Diagnosis
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".
Deadline for manuscript submissions: 30 November 2026 | Viewed by 2058
Special Issue Editor
Interests: Parkinson’s disease; alpha-synuclein; dopaminergic neuron; apoptosis; neuroinflammation; acupuncture; neuroprotection
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to announce a Special Issue dedicated to exploring the pivotal role of biomarkers in understanding, diagnosing, and treating neurodegenerative diseases. This Special Issue aims to showcase cutting-edge research on molecular biomarkers that are revolutionizing our approach to neurodegeneration, with particular emphasis on protein aggregation pathways, including but not limited to alpha-synuclein, tau, amyloid-β, and TDP-43.
As these pathological proteins serve as both critical biomarkers and promising therapeutic targets, we seek to bridge the gap between molecular discovery and clinical application, fostering interdisciplinary collaboration across the neurodegenerative disease spectrum.
Scope and Topics of Interest
In this Special Issue, original research articles, comprehensive reviews, and perspectives are welcome. Research areas may include (but are not limited to) the following:
- Molecular Mechanisms and Pathophysiology
- Protein aggregation, misfolding, and prion-like propagation mechanisms.
- Post-translational modifications and their role in disease progression.
- Cellular stress responses and proteostasis networks.
- Biomarker Discovery and Validation
- Novel fluid-based biomarkers (blood, CSF, saliva, tears).
- Extracellular vesicles and their cargo as diagnostic tools.
- Multi-omics approaches for biomarker identification.
- Digital and wearable biomarkers for early detection.
- Advanced Diagnostic Technologies
- Next-generation imaging techniques and molecular PET tracers.
- Ultra-sensitive detection methods (Simoa, mass spectrometry, biosensors).
- AI-driven diagnostic algorithms and predictive modeling.
- Point-of-care diagnostic platform development.
- Therapeutic Strategies and Clinical Translation
- Immunotherapy approaches targeting pathological proteins.
- Small molecule modulators of protein aggregation.
- Gene and RNA-based therapeutic interventions.
- Biomarker-guided clinical trial design and patient stratification.
- Translational and Implementation Science
- Longitudinal studies tracking biomarker dynamics.
- Standardization and harmonization of biomarker assays.
- Health economics and accessibility of biomarker testing.
- Precision medicine approaches using biomarker profiles.
This Special Issue aims to provide a comprehensive overview of current advances in neurodegenerative disease biomarkers while identifying critical gaps and future directions. We particularly encourage submissions that demonstrate translational potential, moving from mechanistic insights to clinical applications that will ultimately benefit patients affected by these devastating diseases.
We welcome contributions from researchers across disciplines, including neuroscience, molecular biology, clinical neurology, bioengineering, and computational biology, fostering an integrative approach to tackling the challenges of neurodegeneration.
I look forward to receiving your contributions.
Dr. Sujung Yeo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- alpha-synuclein
- neurodegeneration
- Parkinson's disease
- pathophysiology
- mechanism
- therapy
- synucleinopathy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
